



ALEMBIC LIMITED
Regd. Office: Alembic Road, Vadodara 390 003

**UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST DECEMBER, 2008**

(Rs. in Lacs)

Particulars	Quarter Ended on 31st December 2008 (Reviewed)	Quarter Ended on 31st December 2007 (Reviewed)	Nine Month Ended on 31st December 2008 (Reviewed)	Nine Month Ended on 31st December 2007 (Reviewed)	Previous Accounting year ended on 31st March, 2008 (Audited)
1 (a) Net Sales / Income from Operations					
Domestic	18997	17363	53613	54600	71076
Exports	9600	9163	33848	21252	31585
Total	28597	26526	87461	75852	102661
Less : Excise Duty	328	464	1449	1807	2336
Net Sales / Income from Operations	28269	26062	86012	74045	100325
(b) Other Operating Income	104	218	353	379	518
Total Income	28373	26280	86365	74424	100843
2 Expenditure					
(a) Decrease/(increase) in stock in trade and work in progress	(1177)	(1259)	(2363)	(2608)	(1892)
(b) Consumption of Raw Materials & Packing Materials	11723	9773	33923	23254	33012
(c) Purchase of traded goods	3064	4256	10998	14328	17228
(d) Employees' Cost	3438	2590	9695	7165	9762
(e) Depreciation	976	838	2849	2402	3277
(f) Research and Development Expense	849	1120	2512	3367	4339
(g) Excise Duty	176	398	823	847	881
(h) Other Expenditure	7278	6239	19358	16501	22484
Total	26327	23955	77795	65256	89091
3 Profit from Operations before Other Income, Interest, Foreign Exchange gain / (loss) & Exceptional Items	2046	2325	8570	9168	11752
4 Other Income	24	403	85	511	577
5 Profit/(Loss) before Interest, Foreign Exchange gain / (loss) & Exceptional Items	2070	2728	8655	9679	12329
6 Interest (Net)	1114	838	3292	2383	3305
7 Profit/(Loss) after Interest but before Foreign Exchange gain / (loss) & Exceptional Items	956	1890	5363	7296	9024
8 Foreign Exchange gain / (loss) (Net)	(170)	97	(3465)	257	81
9 Profit / (Loss) before Exceptional Items	786	1987	1898	7553	9105
10 Exceptional Items					
Add : Profit on sale of Land	-	2255	-	2255	2255
Less : Provision for Diminution in Investment	(752)	-	(752)	-	-
Intangible Asset Written off					17682
Less : Transfer from General Reserve	-	-	-	-	10258
Less : Transfer from Share Premium Account	-	-	-	-	2917
Less : Deferred Tax Asset	-	-	-	-	4507
11 Net Profit / (Loss) from Ordinary Activities before Tax	34	4242	1146	9808	11360
12 Tax Expense					
Less : Provision for Fringe Benefit Tax & Wealth Tax	62	50	150	103	148
Less : Provision for Current Tax	3	-	128	-	-
Less/(Add) : Provision for Deferred Tax Liability/(Assets)	(16)	(10)	25	20	47
Add : Provision of Income Tax of earlier years written back (Net)	223	-	399	-	54
13 Net Profit / (Loss) from Ordinary Activities after Tax	208	4202	1242	9685	11219
14 Paid up Equity Share Capital (Face value of share Rs 2/-)	2767	2769	2767	2769	2769
15 Reserves excluding Revaluation Reserve					31367
16 Earnings Per Share (EPS)					
Basic & Diluted EPS after Extraordinary items	0.15	3.04	0.90	7.00	8.10
17 Public Shareholding					
- Number of Shares	53591652	53701900			53701900
- Percentage of Shareholding	38.74	38.79			38.79

Notes :

- 1 The above results, duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors.
- 2 The Company is engaged in Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS - 17)
- 3 Foreign Exchange gain / (loss) - (Net) includes realized and unrealized exchange gain/ (loss) on restatement of foreign currency borrowing and forward sale of US dollars.
- 4 In terms of decision of the Board of Directors dated November 14, 2008 the Company offered to buy back its equity shares of face value of Rs.2/- each, upto a maximum amount of Rs.3300 lakhs at a maximum price of Rs.55/- per share through the methodology of "Open market purchases through stock exchanges" using the electronic trading facilities of the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE). After completion of regulatory formalities, the Company commenced the buy back on December 8, 2008.

As on December 31, 2008 the Company has bought back 1,10,248 equity shares at an average price of Rs. 32.03 for a total consideration of Rs. 35.32 lacs which is about 1.07% of the total buy – back size of Rs. 3300 lacs. In terms of the provisions of section 77A of the Companies Act, 1956 and SEBI (Buy Back of Securities) Regulations, 1998, the Company has extinguished the said shares on or before 31.12.2008.

- 5 Alembic Limited had made an strategic investment in December 2003 in Xechem International Inc, USA, pursuant to which Alembic invested \$ 640,000 as Equity and lent \$3 million as optionally convertible loan. Xechem had a patent and it was working on commercialization of NISCOSAN™, a product used in the management of the symptoms of Sick Cell Disease (SDS).

The project did not progress as per initial plans and hence Alembic terminated loan agreement and MOU, demanded refund of loan. Alembic Limited was able to subsequently get refund of \$2 million loan.

Xechem has filed for bankruptcy proceedings in USA on 9th November 2008. As on date, Alembic's exposure to Xechem (at cost) is as under:-

1	Equity US\$ 640,000	Rs 2.90	Crores
2	Loan (convertible) – US\$ 1 Million	Rs 4.62	Crores
	Total Amount	Rs 7.52	Crores

As a prudent practice, provision has been made in books of accounts in Q3FY09 for the above amount.

- 6 Profit for the quarter got adversely affected on account of higher material cost and lower Penicillin-G realizations for API business.
For Domestic formulations business, gestation period for deriving benefits of significant investments made in resources and growth initiatives has taken longer than anticipated. However current trend witnessed has been positive.
- 7 Details of Investors' Complaints for the quarter ended on 31st December, 2008 : Unresolved at the beginning of the quarter-NIL
Received during the quarter-23, Disposed off during the quarter-23 , Unresolved at the end of the quarter - NIL.
- 8 The previous quarter's / period's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period.

For Alembic Limited

Place : Vadodara
Date : 28th January, 2009

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com